IceCure MedicalICCM
ICCM
About: Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
Employees: 66
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
43% more capital invested
Capital invested by funds: $118K [Q3] → $169K (+$50.8K) [Q4]
0.11% less ownership
Funds ownership: 0.39% [Q3] → 0.28% (-0.11%) [Q4]
13% less funds holding
Funds holding: 15 [Q3] → 13 (-2) [Q4]
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$2.50
98%
upside
Avg. target
$2.50
98%
upside
High target
$2.50
98%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Yi Chen 33% 1-year accuracy 57 / 173 met price target | 98%upside $2.50 | Buy Reiterated | 28 Mar 2025 |
Financial journalist opinion
Based on 3 articles about ICCM published over the past 30 days
Neutral
PRNewsWire
15 hours ago
IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer
Final marketing authorization decision for early-stage breast cancer is expected upon the FDA's approval of IceCure's post-market study plan IceCure to engage with potential clinical sites, breast surgeons and radiologists for the post-market study including at the upcoming American Society of Breast Surgeons (ASBrS) Annual Meeting ProSense® would become the first-in-class minimally invasive choice—a major advancement in women's health and a new paradigm in breast cancer care as a simple out-patient procedure U.S. sales and distribution team ready to drive sales of ProSense® systems and disposable probes—supporting medical community and patients looking for a new minimally invasive option to lumpectomy CAESAREA, Israel , April 30, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it concluded a productive meeting with the leadership of the U.S. Food and Drug Administration's ("FDA") Center for Devices and Radiological Health ("CDRH") regarding the Company's De Novo marketing authorization request for ProSense® in the treatment of early-stage low risk breast cancer when combined with adjuvant endocrine therapy for women aged 70 and over which represents approximately 46,000 patients annually in the U.S. During the meeting, the FDA requested that IceCure conduct a study after marketing authorization has been granted ("the post-market study"), with the aim of producing additional data in this indication.
Neutral
PRNewsWire
2 days ago
IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium
Two sold-out SBI breast cryoablation courses featured hands-on training with ProSense® IceCure hosted a VIP Exhibitor Hour featuring Dr. Robert C. Ward, a specialist in women's imaging and breast cryoablation CAESAREA, Israel , April 28, 2025 /PRNewswire/ -- IceCure Medical Ltd.
Neutral
PRNewsWire
1 week ago
IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation
Breast cancer cryoablation was a major focus at ECIO 2025 with a dedicated scientific session Independent studies of ProSense® featured in scientific sessions and abstracts including data from the THERMAC trial stating 95% of patients said they would choose thermal ablation over breast conserving surgery In-booth expert exchange session on breast cancer cryoablation from the perspective of both breast surgeons and interventional oncologists by Sophie Wooldrik, MD & Prof. Tomas Vogl, MD respectively Three hands-on device trainings, including ProSense® CAESAREA, Israel , April 22, 2025 /PRNewswire/ -- IceCure Medical Ltd.
Positive
Zacks Investment Research
1 month ago
IceCure Medical Stock Dips Despite Positive ICESECRET Study Results
ICCM reports strong kidney cancer cryoablation study results, showcasing 88.7% recurrence-free rates and reinforcing its position in cryoablation technology.
Neutral
Seeking Alpha
1 month ago
IceCure Medical Ltd (ICCM) Q4 2024 Earnings Call Transcript
IceCure Medical Ltd (NASDAQ:ICCM ) Q4 2024 Earnings Conference Call March 27, 2025 10:00 AM ET Company Participants Michael Polyviou - Investor Relations Eyal Shamir - Chief Executive Officer and Director Ronen Tsimerman - Chief Financial Officer and Chief Operating Officer Conference Call Participants Kemp Dolliver - Brookline Capital Markets Anthony Vendetti - Maxim Group Operator Good morning, and thank you for standing by. Currently, all the participants' are in a listen-only mode.
Neutral
PRNewsWire
1 month ago
IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America
Expecting FDA decision on marketing authorization for early-stage low risk breast cancer with endocrine therapy Positive ProSense® results were reported through 33 peer-reviewed journals and medical conferences during 2024 Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel , March 27, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the twelve months ended December 31, 2024.
Neutral
PRNewsWire
1 month ago
IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate
Interim Data confirm ProSense® cryoablation is highly effective for kidney tumors ≤3 cm and a safe procedure for kidney tumors ≤5 cm in people ineligible for surgery CAESAREA, Israel , March 24, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that interim results from the Company's ICESECRET study of cryoablation for patients with small renal masses ("SRM") who cannot be offered kidney preserving surgery were presented at the European Association of Urology Conference in Madrid, Spain which took place March 21-24, 2025.
Neutral
PRNewsWire
1 month ago
IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025
CAESAREA, Israel , March 21, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the twelve months ended December 31, 2024 before the Nasdaq Stock Market opens on Thursday, March 27, 2025.
Neutral
PRNewsWire
1 month ago
IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer
IceCure working in close collaboration with FDA towards De Novo decision CAESAREA, Israel , March 20, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it is in continued discussions with the U.S. Food and Drug Administration ("FDA") regarding its De Novo marketing authorization request for ProSense® in early-stage low risk breast cancer with endocrine therapy.
Neutral
PRNewsWire
1 month ago
IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference
IceCure exhibited at the prestigious event in Vienna, Austria attended by oncologists, breast surgeons An abstract on ICE3 study results by Dr. Richard Fine was accepted and included in the poster presentation gallery An independent study by Dr. Ava Kwong evaluated expanding the ICE3 study population to include triple negative breast cancer and younger patients Four additional independent abstracts were presented at the conference and all six will be published in the scientific journal—The Breast CAESAREA, Israel , March 18, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it exhibited at the 19th Annual St. Gallen Breast Cancer Conference in Vienna, Austria from March 12 – 15, 2025.
Charts implemented using Lightweight Charts™